Time in bed of patients undergoing a cardiac procedure, baseline results of the PACO study

Sleep affects cardiovascular health in many ways, and for example, a connection between sleep disorders and coronary artery disease has been discovered. The aim of this study is to investigate the sleep of patients undergoing a cardiac procedure and compare it with healthy Finnish controls sleep. The study is based on the baseline results from the PACO study (Personalized intervention to increase physical Activity and reduce sedentary behaviour in rehabilitation after Cardiac Operations). The study population consists of 265 cardiac patients divided into four groups based on the cardiac procedure: coronary intervention or coronary angiography, isolated coronary artery bypass grafting, aortic valve replacement and mitral valve surgery. Patients carried an accelerometer seven days preoperatively. During the day the accelerometer was on the hip and at night it was moved to the wrist to optimize sleep monitoring. The accelerometer data was analyzed to calculate patients time in bed (TIB) and TIB was divided into three different categories based on how many movements occurred within a certain epoch. The controls were from the population based FinFit2017 study, matched for age and gender, and their sleep had been monitored with similar accelerometer. The study revealed that the TIB and the time awake in bed was statistically significantly longer in study population than in controls, but no clear differences were noticed in the amount of sleep. This may indicate that heart patients try to get more sleep than general population but take longer to fall asleep or wake up more at night

MANTA versus ProGlide vascular closure devices in transfemoral transcatheter aortic valve implantation

Background: The MANTA system is a novel vascular closure device (VCD) and its safety and efficacy were compared to the ProGlide VCD in patients undergoing transfemoral transcatheter aortic valve implantation (TAVI).Methods: This is a retrospective study including 222 patients who underwent transfemoral TAVI at three Finnish University Hospitals. The MANTA VCD was used in 107 patients and their outcome was compared with that of 115 patients in whom the arterial access was closed with the ProGlide VCD.Results: VARC-2 VCD failure occurred less frequently in the MANTA cohort (3.7% vs. 7.8%, p = 0378), but the difference did not reach statistical significance. When adjusted for the introducer outer diameter, the MANTA cohort had similar rates of VARC-2 major vascular complications (93% vs. 12.2%, adjusted: p = 0.456), VARC-2 life-threatening/disabling bleeding (93% vs. 6.1%, adjusted: p = 0.296) and need of invasive treatment of bleeding (4.7% vs. 7.0%, adjusted: p = 0.416) compared to the ProGlide cohort. Additional VCDs were more frequently needed in the ProGlide cohort (583% vs. 1.9%, p Conclusions: In patients undergoing transfemoral TAVI, the MANTA VCD showed a similar risk of VARC-2 vascular and bleeding complications compared to the ProGlide VCD, but it reduced significantly the need of additional VCDs for completion of hemostasis.</p

MANTA versus ProGlide vascular closure devices in transfemoral transcatheter aortic valve implantation

Abstract Background: The MANTA system is a novel vascular closure device (VCD) and its safety and efficacy were compared to the ProGlide VCD in patients undergoing transfemoral transcatheter aortic valve implantation (TAVI). Methods: This is a retrospective study including 222 patients who underwent transfemoral TAVI at three Finnish University Hospitals. The MANTA VCD was used in 107 patients and their outcome was compared with that of 115 patients in whom the arterial access was closed with the ProGlide VCD. Results: VARC-2 VCD failure occurred less frequently in the MANTA cohort (3.7% vs. 7.8%, p = 0.378), but the difference did not reach statistical significance. When adjusted for the introducer outer diameter, the MANTA cohort had similar rates of VARC-2 major vascular complications (9.3% vs. 12.2%, adjusted: p = 0.456), VARC-2 life-threatening/disabling bleeding (9.3% vs. 6.1%, adjusted: p = 0.296) and need of invasive treatment of bleeding (4.7% vs. 7.0%, adjusted: p = 0.416) compared to the ProGlide cohort. Additional VCDs were more frequently needed in the ProGlide cohort (58.3% vs. 1.9%, p < 0.0001). Conclusions: In patients undergoing transfemoral TAVI, the MANTA VCD showed a similar risk of VARC-2 vascular and bleeding complications compared to the ProGlide VCD, but it reduced significantly the need of additional VCDs for completion of hemostasis